img

Global Novel Coronavirus (COVID-19) Vaccine Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Latest Trends

Publisher : MRA | Format : PDF

Global Novel Coronavirus (COVID-19) Vaccine Market Research Report 2024

According to MRA Research’s new survey, global Novel Coronavirus (COVID-19) Vaccine market is projected to reach US$ million in 2033, increasing from US$ million in 2023, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Novel Coronavirus (COVID-19) Vaccine market research.
The global pharmaceutical market is 1475 billion USD in 2023, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2023. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2023. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2023) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Novel Coronavirus (COVID-19) Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Inovio Pharmaceuticals
Takis Biotech (Evvivax)
Zydus Cadila
Codagenix, Inc.
GeoVax, Inc.
Bravovax
Janssen Pharmaceutical Companies
Altimmune
Vaxart
CanSino Biologics
ExpreS2ion Biotechnologies ApS
Clover Biopharmaceuticals
GSK
Vaxil Bio Ltd.
Generex
Novavax, Inc.
Sanofi Pasteur
Baylor
iBio, Inc.
Moderna, Inc.
Curevac
ImmunoPrecise
Segment by Type
DNA
RNA
Others

Segment by Application


Mild Symptom Patient
Critically Ill Patient
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Novel Coronavirus (COVID-19) Vaccine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Type: 2018 VS 2023 VS 2033
1.2.2 DNA
1.2.3 RNA
1.2.4 Others
1.3 Market by Application
1.3.1 Global Novel Coronavirus (COVID-19) Vaccine Market Growth by Application: 2018 VS 2023 VS 2033
1.3.2 Mild Symptom Patient
1.3.3 Critically Ill Patient
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Novel Coronavirus (COVID-19) Vaccine Market Perspective (2018-2033)
2.2 Novel Coronavirus (COVID-19) Vaccine Growth Trends by Region
2.2.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size by Region: 2018 VS 2023 VS 2033
2.2.2 Novel Coronavirus (COVID-19) Vaccine Historic Market Size by Region (2018-2023)
2.2.3 Novel Coronavirus (COVID-19) Vaccine Forecasted Market Size by Region (2024-2033)
2.3 Novel Coronavirus (COVID-19) Vaccine Market Dynamics
2.3.1 Novel Coronavirus (COVID-19) Vaccine Industry Trends
2.3.2 Novel Coronavirus (COVID-19) Vaccine Market Drivers
2.3.3 Novel Coronavirus (COVID-19) Vaccine Market Challenges
2.3.4 Novel Coronavirus (COVID-19) Vaccine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Novel Coronavirus (COVID-19) Vaccine Players by Revenue
3.1.1 Global Top Novel Coronavirus (COVID-19) Vaccine Players by Revenue (2018-2023)
3.1.2 Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Players (2018-2023)
3.2 Global Novel Coronavirus (COVID-19) Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Novel Coronavirus (COVID-19) Vaccine Revenue
3.4 Global Novel Coronavirus (COVID-19) Vaccine Market Concentration Ratio
3.4.1 Global Novel Coronavirus (COVID-19) Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Novel Coronavirus (COVID-19) Vaccine Revenue in 2023
3.5 Novel Coronavirus (COVID-19) Vaccine Key Players Head office and Area Served
3.6 Key Players Novel Coronavirus (COVID-19) Vaccine Product Solution and Service
3.7 Date of Enter into Novel Coronavirus (COVID-19) Vaccine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Novel Coronavirus (COVID-19) Vaccine Breakdown Data by Type
4.1 Global Novel Coronavirus (COVID-19) Vaccine Historic Market Size by Type (2018-2023)
4.2 Global Novel Coronavirus (COVID-19) Vaccine Forecasted Market Size by Type (2024-2033)
5 Novel Coronavirus (COVID-19) Vaccine Breakdown Data by Application
5.1 Global Novel Coronavirus (COVID-19) Vaccine Historic Market Size by Application (2018-2023)
5.2 Global Novel Coronavirus (COVID-19) Vaccine Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033)
6.2 North America Novel Coronavirus (COVID-19) Vaccine Market Growth Rate by Country: 2018 VS 2023 VS 2033
6.3 North America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2018-2023)
6.4 North America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033)
7.2 Europe Novel Coronavirus (COVID-19) Vaccine Market Growth Rate by Country: 2018 VS 2023 VS 2033
7.3 Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2018-2023)
7.4 Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033)
8.2 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Growth Rate by Region: 2018 VS 2023 VS 2033
8.3 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size by Region (2018-2023)
8.4 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033)
9.2 Latin America Novel Coronavirus (COVID-19) Vaccine Market Growth Rate by Country: 2018 VS 2023 VS 2033
9.3 Latin America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2018-2023)
9.4 Latin America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Size (2018-2033)
10.2 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Growth Rate by Country: 2018 VS 2023 VS 2033
10.3 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2018-2023)
10.4 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Inovio Pharmaceuticals
11.1.1 Inovio Pharmaceuticals Company Detail
11.1.2 Inovio Pharmaceuticals Business Overview
11.1.3 Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Introduction
11.1.4 Inovio Pharmaceuticals Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.1.5 Inovio Pharmaceuticals Recent Development
11.2 Takis Biotech (Evvivax)
11.2.1 Takis Biotech (Evvivax) Company Detail
11.2.2 Takis Biotech (Evvivax) Business Overview
11.2.3 Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Introduction
11.2.4 Takis Biotech (Evvivax) Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.2.5 Takis Biotech (Evvivax) Recent Development
11.3 Zydus Cadila
11.3.1 Zydus Cadila Company Detail
11.3.2 Zydus Cadila Business Overview
11.3.3 Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Introduction
11.3.4 Zydus Cadila Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.3.5 Zydus Cadila Recent Development
11.4 Codagenix, Inc.
11.4.1 Codagenix, Inc. Company Detail
11.4.2 Codagenix, Inc. Business Overview
11.4.3 Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction
11.4.4 Codagenix, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.4.5 Codagenix, Inc. Recent Development
11.5 GeoVax, Inc.
11.5.1 GeoVax, Inc. Company Detail
11.5.2 GeoVax, Inc. Business Overview
11.5.3 GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction
11.5.4 GeoVax, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.5.5 GeoVax, Inc. Recent Development
11.6 Bravovax
11.6.1 Bravovax Company Detail
11.6.2 Bravovax Business Overview
11.6.3 Bravovax Novel Coronavirus (COVID-19) Vaccine Introduction
11.6.4 Bravovax Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.6.5 Bravovax Recent Development
11.7 Janssen Pharmaceutical Companies
11.7.1 Janssen Pharmaceutical Companies Company Detail
11.7.2 Janssen Pharmaceutical Companies Business Overview
11.7.3 Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Introduction
11.7.4 Janssen Pharmaceutical Companies Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.7.5 Janssen Pharmaceutical Companies Recent Development
11.8 Altimmune
11.8.1 Altimmune Company Detail
11.8.2 Altimmune Business Overview
11.8.3 Altimmune Novel Coronavirus (COVID-19) Vaccine Introduction
11.8.4 Altimmune Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.8.5 Altimmune Recent Development
11.9 Vaxart
11.9.1 Vaxart Company Detail
11.9.2 Vaxart Business Overview
11.9.3 Vaxart Novel Coronavirus (COVID-19) Vaccine Introduction
11.9.4 Vaxart Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.9.5 Vaxart Recent Development
11.10 CanSino Biologics
11.10.1 CanSino Biologics Company Detail
11.10.2 CanSino Biologics Business Overview
11.10.3 CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Introduction
11.10.4 CanSino Biologics Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.10.5 CanSino Biologics Recent Development
11.11 ExpreS2ion Biotechnologies ApS
11.11.1 ExpreS2ion Biotechnologies ApS Company Detail
11.11.2 ExpreS2ion Biotechnologies ApS Business Overview
11.11.3 ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Introduction
11.11.4 ExpreS2ion Biotechnologies ApS Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.11.5 ExpreS2ion Biotechnologies ApS Recent Development
11.12 Clover Biopharmaceuticals
11.12.1 Clover Biopharmaceuticals Company Detail
11.12.2 Clover Biopharmaceuticals Business Overview
11.12.3 Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Introduction
11.12.4 Clover Biopharmaceuticals Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.12.5 Clover Biopharmaceuticals Recent Development
11.13 GSK
11.13.1 GSK Company Detail
11.13.2 GSK Business Overview
11.13.3 GSK Novel Coronavirus (COVID-19) Vaccine Introduction
11.13.4 GSK Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.13.5 GSK Recent Development
11.14 Vaxil Bio Ltd.
11.14.1 Vaxil Bio Ltd. Company Detail
11.14.2 Vaxil Bio Ltd. Business Overview
11.14.3 Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Introduction
11.14.4 Vaxil Bio Ltd. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.14.5 Vaxil Bio Ltd. Recent Development
11.15 Generex
11.15.1 Generex Company Detail
11.15.2 Generex Business Overview
11.15.3 Generex Novel Coronavirus (COVID-19) Vaccine Introduction
11.15.4 Generex Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.15.5 Generex Recent Development
11.16 Novavax, Inc.
11.16.1 Novavax, Inc. Company Detail
11.16.2 Novavax, Inc. Business Overview
11.16.3 Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction
11.16.4 Novavax, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.16.5 Novavax, Inc. Recent Development
11.17 Sanofi Pasteur
11.17.1 Sanofi Pasteur Company Detail
11.17.2 Sanofi Pasteur Business Overview
11.17.3 Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Introduction
11.17.4 Sanofi Pasteur Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.17.5 Sanofi Pasteur Recent Development
11.18 Baylor
11.18.1 Baylor Company Detail
11.18.2 Baylor Business Overview
11.18.3 Baylor Novel Coronavirus (COVID-19) Vaccine Introduction
11.18.4 Baylor Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.18.5 Baylor Recent Development
11.19 iBio, Inc.
11.19.1 iBio, Inc. Company Detail
11.19.2 iBio, Inc. Business Overview
11.19.3 iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction
11.19.4 iBio, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.19.5 iBio, Inc. Recent Development
11.20 Moderna, Inc.
11.20.1 Moderna, Inc. Company Detail
11.20.2 Moderna, Inc. Business Overview
11.20.3 Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction
11.20.4 Moderna, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.20.5 Moderna, Inc. Recent Development
11.21 Curevac
11.21.1 Curevac Company Detail
11.21.2 Curevac Business Overview
11.21.3 Curevac Novel Coronavirus (COVID-19) Vaccine Introduction
11.21.4 Curevac Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.21.5 Curevac Recent Development
11.22 ImmunoPrecise
11.22.1 ImmunoPrecise Company Detail
11.22.2 ImmunoPrecise Business Overview
11.22.3 ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Introduction
11.22.4 ImmunoPrecise Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
11.22.5 ImmunoPrecise Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Type (US$ Million): 2018 VS 2023 VS 2033
Table 2. Key Players of DNA
Table 3. Key Players of RNA
Table 4. Key Players of Others
Table 5. Global Novel Coronavirus (COVID-19) Vaccine Market Size Growth by Application (US$ Million): 2018 VS 2023 VS 2033
Table 6. Global Novel Coronavirus (COVID-19) Vaccine Market Size by Region (US$ Million): 2018 VS 2023 VS 2033
Table 7. Global Novel Coronavirus (COVID-19) Vaccine Market Size by Region (2018-2023) & (US$ Million)
Table 8. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Region (2018-2023)
Table 9. Global Novel Coronavirus (COVID-19) Vaccine Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 10. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Region (2024-2033)
Table 11. Novel Coronavirus (COVID-19) Vaccine Market Trends
Table 12. Novel Coronavirus (COVID-19) Vaccine Market Drivers
Table 13. Novel Coronavirus (COVID-19) Vaccine Market Challenges
Table 14. Novel Coronavirus (COVID-19) Vaccine Market Restraints
Table 15. Global Novel Coronavirus (COVID-19) Vaccine Revenue by Players (2018-2023) & (US$ Million)
Table 16. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Players (2018-2023)
Table 17. Global Top Novel Coronavirus (COVID-19) Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Novel Coronavirus (COVID-19) Vaccine as of 2023)
Table 18. Ranking of Global Top Novel Coronavirus (COVID-19) Vaccine Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Novel Coronavirus (COVID-19) Vaccine Revenue (CR5 and HHI) & (2018-2023)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Novel Coronavirus (COVID-19) Vaccine Product Solution and Service
Table 22. Date of Enter into Novel Coronavirus (COVID-19) Vaccine Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2018-2023) & (US$ Million)
Table 25. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type (2018-2023)
Table 26. Global Novel Coronavirus (COVID-19) Vaccine Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 27. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type (2024-2033)
Table 28. Global Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2018-2023) & (US$ Million)
Table 29. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Application (2018-2023)
Table 30. Global Novel Coronavirus (COVID-19) Vaccine Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 31. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Application (2024-2033)
Table 32. North America Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Country (US$ Million): 2018 VS 2023 VS 2033
Table 33. North America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2018-2023) & (US$ Million)
Table 34. North America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2024-2033) & (US$ Million)
Table 35. Europe Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Country (US$ Million): 2018 VS 2023 VS 2033
Table 36. Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2018-2023) & (US$ Million)
Table 37. Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2024-2033) & (US$ Million)
Table 38. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Region (US$ Million): 2018 VS 2023 VS 2033
Table 39. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size by Region (2018-2023) & (US$ Million)
Table 40. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size by Region (2024-2033) & (US$ Million)
Table 41. Latin America Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Country (US$ Million): 2018 VS 2023 VS 2033
Table 42. Latin America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2018-2023) & (US$ Million)
Table 43. Latin America Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2024-2033) & (US$ Million)
Table 44. Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Country (US$ Million): 2018 VS 2023 VS 2033
Table 45. Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2018-2023) & (US$ Million)
Table 46. Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Size by Country (2024-2033) & (US$ Million)
Table 47. Inovio Pharmaceuticals Company Detail
Table 48. Inovio Pharmaceuticals Business Overview
Table 49. Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product
Table 50. Inovio Pharmaceuticals Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 51. Inovio Pharmaceuticals Recent Development
Table 52. Takis Biotech (Evvivax) Company Detail
Table 53. Takis Biotech (Evvivax) Business Overview
Table 54. Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Product
Table 55. Takis Biotech (Evvivax) Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 56. Takis Biotech (Evvivax) Recent Development
Table 57. Zydus Cadila Company Detail
Table 58. Zydus Cadila Business Overview
Table 59. Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Product
Table 60. Zydus Cadila Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 61. Zydus Cadila Recent Development
Table 62. Codagenix, Inc. Company Detail
Table 63. Codagenix, Inc. Business Overview
Table 64. Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Product
Table 65. Codagenix, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 66. Codagenix, Inc. Recent Development
Table 67. GeoVax, Inc. Company Detail
Table 68. GeoVax, Inc. Business Overview
Table 69. GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Product
Table 70. GeoVax, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 71. GeoVax, Inc. Recent Development
Table 72. Bravovax Company Detail
Table 73. Bravovax Business Overview
Table 74. Bravovax Novel Coronavirus (COVID-19) Vaccine Product
Table 75. Bravovax Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 76. Bravovax Recent Development
Table 77. Janssen Pharmaceutical Companies Company Detail
Table 78. Janssen Pharmaceutical Companies Business Overview
Table 79. Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Product
Table 80. Janssen Pharmaceutical Companies Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 81. Janssen Pharmaceutical Companies Recent Development
Table 82. Altimmune Company Detail
Table 83. Altimmune Business Overview
Table 84. Altimmune Novel Coronavirus (COVID-19) Vaccine Product
Table 85. Altimmune Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 86. Altimmune Recent Development
Table 87. Vaxart Company Detail
Table 88. Vaxart Business Overview
Table 89. Vaxart Novel Coronavirus (COVID-19) Vaccine Product
Table 90. Vaxart Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 91. Vaxart Recent Development
Table 92. CanSino Biologics Company Detail
Table 93. CanSino Biologics Business Overview
Table 94. CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Product
Table 95. CanSino Biologics Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 96. CanSino Biologics Recent Development
Table 97. ExpreS2ion Biotechnologies ApS Company Detail
Table 98. ExpreS2ion Biotechnologies ApS Business Overview
Table 99. ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Product
Table 100. ExpreS2ion Biotechnologies ApS Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 101. ExpreS2ion Biotechnologies ApS Recent Development
Table 102. Clover Biopharmaceuticals Company Detail
Table 103. Clover Biopharmaceuticals Business Overview
Table 104. Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product
Table 105. Clover Biopharmaceuticals Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 106. Clover Biopharmaceuticals Recent Development
Table 107. GSK Company Detail
Table 108. GSK Business Overview
Table 109. GSK Novel Coronavirus (COVID-19) Vaccine Product
Table 110. GSK Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 111. GSK Recent Development
Table 112. Vaxil Bio Ltd. Company Detail
Table 113. Vaxil Bio Ltd. Business Overview
Table 114. Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Product
Table 115. Vaxil Bio Ltd. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 116. Vaxil Bio Ltd. Recent Development
Table 117. Generex Company Detail
Table 118. Generex Business Overview
Table 119. Generex Novel Coronavirus (COVID-19) Vaccine Product
Table 120. Generex Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 121. Generex Recent Development
Table 122. Novavax, Inc. Company Detail
Table 123. Novavax, Inc. Business Overview
Table 124. Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Product
Table 125. Novavax, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 126. Novavax, Inc. Recent Development
Table 127. Sanofi Pasteur Company Detail
Table 128. Sanofi Pasteur Business Overview
Table 129. Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Product
Table 130. Sanofi Pasteur Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 131. Sanofi Pasteur Recent Development
Table 132. Baylor Company Detail
Table 133. Baylor Business Overview
Table 134. Baylor Novel Coronavirus (COVID-19) Vaccine Product
Table 135. Baylor Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 136. Baylor Recent Development
Table 137. iBio, Inc. Company Detail
Table 138. iBio, Inc. Business Overview
Table 139. iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Product
Table 140. iBio, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 141. iBio, Inc. Recent Development
Table 142. Moderna, Inc. Company Detail
Table 143. Moderna, Inc. Business Overview
Table 144. Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Product
Table 145. Moderna, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 146. Moderna, Inc. Recent Development
Table 147. Curevac Company Detail
Table 148. Curevac Business Overview
Table 149. Curevac Novel Coronavirus (COVID-19) Vaccine Product
Table 150. Curevac Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 151. Curevac Recent Development
Table 152. ImmunoPrecise Company Detail
Table 153. ImmunoPrecise Business Overview
Table 154. ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Product
Table 155. ImmunoPrecise Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023) & (US$ Million)
Table 156. ImmunoPrecise Recent Development
Table 157. Research Programs/Design for This Report
Table 158. Key Data Information from Secondary Sources
Table 159. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Novel Coronavirus (COVID-19) Vaccine Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Type: 2023 VS 2033
Figure 3. DNA Features
Figure 4. RNA Features
Figure 5. Others Features
Figure 6. Global Novel Coronavirus (COVID-19) Vaccine Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 7. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Application: 2023 VS 2033
Figure 8. Mild Symptom Patient Case Studies
Figure 9. Critically Ill Patient Case Studies
Figure 10. Novel Coronavirus (COVID-19) Vaccine Report Years Considered
Figure 11. Global Novel Coronavirus (COVID-19) Vaccine Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 12. Global Novel Coronavirus (COVID-19) Vaccine Market Size, (US$ Million), 2018 VS 2023 VS 2033
Figure 13. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Region: 2023 VS 2033
Figure 14. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Players in 2023
Figure 15. Global Top Novel Coronavirus (COVID-19) Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Novel Coronavirus (COVID-19) Vaccine as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Novel Coronavirus (COVID-19) Vaccine Revenue in 2023
Figure 17. North America Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 18. North America Novel Coronavirus (COVID-19) Vaccine Market Share by Country (2018-2033)
Figure 19. United States Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 20. Canada Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. Europe Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Europe Novel Coronavirus (COVID-19) Vaccine Market Share by Country (2018-2033)
Figure 23. Germany Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. France Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. U.K. Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. Italy Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. Russia Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Nordic Countries Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Share by Region (2018-2033)
Figure 31. China Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Japan Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. South Korea Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Southeast Asia Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. India Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Australia Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Latin America Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Latin America Novel Coronavirus (COVID-19) Vaccine Market Share by Country (2018-2033)
Figure 39. Mexico Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Brazil Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Share by Country (2018-2033)
Figure 43. Turkey Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Saudi Arabia Novel Coronavirus (COVID-19) Vaccine Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Inovio Pharmaceuticals Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 46. Takis Biotech (Evvivax) Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 47. Zydus Cadila Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 48. Codagenix, Inc. Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 49. GeoVax, Inc. Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 50. Bravovax Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 51. Janssen Pharmaceutical Companies Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 52. Altimmune Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 53. Vaxart Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 54. CanSino Biologics Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 55. ExpreS2ion Biotechnologies ApS Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 56. Clover Biopharmaceuticals Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 57. GSK Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 58. Vaxil Bio Ltd. Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 59. Generex Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 60. Novavax, Inc. Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 61. Sanofi Pasteur Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 62. Baylor Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 63. iBio, Inc. Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 64. Moderna, Inc. Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 65. Curevac Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 66. ImmunoPrecise Revenue Growth Rate in Novel Coronavirus (COVID-19) Vaccine Business (2018-2023)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed